藥房的黃昏：Boots 與上市的幻夢

 

藥房的黃昏：Boots 與上市的幻夢

Boots 創立於 1849 年，曾是英國大街小巷的靈魂。然而過去二十年，這家老字號被像二手車一樣在各家私募股權基金間轉手。從與 Alliance Unichem 合併，到淪為 KKR、Walgreens 的囊中物，再到如今的 Sycamore Partners，Boots 經歷了殘酷的「榨乾」過程，長期缺乏戰略投資。雖然近期的翻新與彩妝系列帶來了微薄獲利，但市場傳聞的上市（IPO）計畫，與其說是戰略規劃，不如說是一場急於套現的白日夢。

為什麼兩三年內上市簡直是天方夜譚？首先，大環境對傳統零售極度不友善。Boots 賣的是感冒藥和護膚品，這在當今講求 AI 與科技概念的資本市場中，屬於絕對的「悶股」。若沒有科技光環加持，想要溢價上市簡直難如登天。其次，英國目前的稅務環境簡直是企業地獄。國民保險調漲、商業地稅飆升、全球最高等級的最低工資，再加上林林總總的包裝稅與綠色附加稅，實體零售的獲利空間早已被擠壓得所剩無幾。

第三，倫敦證券交易所（LSE）的國際吸引力正日益凋零，逐漸邊緣化。全球資金現在寧願湧向美股科技龍頭或新興市場，誰會願意將大把資金投向一個成交低迷的市場？最後，這是關於「敘事」的競爭。在這個瘋狂炒作太空科技與人工智慧的時代，要如何說服基金經理人，叫他們把數億美元砸在英國小鎮的配鏡部與維他命架上？這裡沒有足以「吹高」股值的性感故事。

歷史不斷重演著相同的教訓：當一個機構停止創新，轉而沉迷於資本運作時，它的衰亡只是時間問題。Boots 能夠存活至今已是奇蹟，但它更像是一個在數位時代勉強維持運作的活化石。

The Dying Pharmacy: Boots and the Mirage of the IPO

 

The Dying Pharmacy: Boots and the Mirage of the IPO

Boots, founded in 1849, is more than a store; it is the skeletal structure of the British High Street. Yet, over the last two decades, it has been treated less like a heritage brand and more like a used car passed between private equity firms. From the 2006 merger with Alliance Unichem to the clutches of KKR, Walgreens, and now Sycamore Partners, Boots has been gutted, flipped, and starved of the long-term investment required to survive the digital age. While a fresh coat of paint and some new makeup lines have nudged profits back into the green, the prospect of an IPO—the dream exit strategy for its current private equity masters—feels less like a financial inevitability and more like a desperate fantasy.

Why is an IPO in the next few years a pipe dream? First, the macroeconomic climate is brutal. Boots is a seller of cold medicine and moisturizer—a "dull" stock in an era that demands AI-driven growth. It cannot rely on the speculative mania that currently inflates tech valuations. Second, the UK has become a fiscal trap. With soaring National Insurance, crushing business rates, and the highest minimum wage pressures in the G7, the regulatory burden on physical retail is a slow-motion strangulation.

Third, the London Stock Exchange (LSE) is fast becoming a global backwater. International capital is flowing toward the US and emerging markets, viewing the LSE with the polite disinterest one shows a dying museum exhibit. Finally, there is the simple, cynical reality of capital allocation. In a world obsessed with space travel and generative AI, convincing a hedge fund manager to sink hundreds of millions into retail units in Doncaster or Cheltenham is a hard sell. There is no "fancy" story here—no revolutionary platform, no scalable software, just shelves of vitamins and eye exams.

History shows us that institutions which stop innovating and start prioritizing financial engineering over customer value eventually disappear. Boots may have survived this long, but it is surviving as a relic in a landscape that has moved on.